

AUGUST 14-16, 2026 | VANCOUVER, CANADA | HYATT REGENCY VANCOUVER



7<sup>TH</sup> VITILIGO INTERNATIONAL CONGRESS

The 7th Vitiligo International Congress (VIC7) will be held August 14-16, 2026, at the Hyatt Regency in Vancouver, Canada. Formerly known as the Vitiligo International Symposium and most recently held in Egypt in 2024, this meeting will bring together 500–600 leading dermatologists, researchers, healthcare professionals, and patient advocates from around the globe. Together, we will share the latest advancements in vitiligo diagnosis, management, and care — united under our inspiring 2026 theme: **Victory Over Vitiligo in Vancouver**. The Scientific Committee invites you to submit abstracts for consideration as oral or poster presentations.

## IMPORTANT DATES

### VIC7 Online Abstract Portal open for submissions

Monday, December 15, 2025

### Abstract Submission Deadline - **EXTENDED**

Friday, April 10, 2026

### Abstract Notification

Friday, May 1, 2026

### Presenting Author Registration Deadline

Wednesday, May 27, 2026

### Presentation at 7th Vitiligo International Congress (VIC7)

August 14-16, 2026

Abstract submissions will only be accepted online via the congress online abstract portal. The **submission deadline is April 10, 2026**. Submitting and presenting authors will be required to submit a disclosure statement. A condition of acceptance is that the **presenting author** must register for the congress and be available to present August 14-16. Confirmation of registration must be received by **May 27, 2026** for the abstract to advance to the Final Program.  
[www.VitiligoCongress.org](http://www.VitiligoCongress.org)

## PUBLICATION AGREEMENT

Authors of accepted abstracts grant the 7th Vitiligo International Congress and the Global Vitiligo Foundation (GVF), its agents and representatives the right to use their names and abstracts in promotional and other materials published in relation to the 7th Vitiligo International Congress.

## AUTHOR ELIGIBILITY

As you prepare for your abstract submission, please note the following eligibility criteria:

- Presenting authors of accepted abstracts (oral or poster) must be present at the Congress, and therefore, must pay the registration fee by the May 27th deadline.

## ABSTRACT FORMAT

Abstract submissions will be reviewed for presentation and may be submitted as

1. Oral presentation, or
2. Poster presentation

As there are a limited number of oral presentations in the program, please understand that we are not able to accept all abstracts as oral presentations. Please ensure to advise if you will accept a poster in the event your abstract is not awarded an oral. Select the appropriate tick box in the abstract submission site.

## SELECTION PROCESS & TOPICS

All abstracts are subject to an anonymous peer-review by members of the 7th Vitiligo International Congress.

Submitting and presenting authors are required to provide a conflict-of-interest disclosure statement. This is required for their abstract to be considered for peer-review and assists in ensuring high-quality, unbiased presentations. Failure to provide a disclosure statement will result in the abstract submission not proceeding to peer-review.

All abstracts submitted must address one of the conference topics for inclusion in the program. When submitting an abstract, please select the topic your abstract applies to from the list to the right.

## NOTIFICATION TIMELINE

Notice of abstract acceptance will be provided **May 1, 2026**. This initial correspondence will be addressed to the **submitting author**. After acceptance, all further correspondence will be directed to the **designated presenting author only**.

Oral presentations will be scheduled during program sessions August 14-16, 2026. Poster presentations will be on display for the duration of the congress. Presenting authors not registered by **Wednesday, May 27, 2026** will forfeit both their invitation to present and inclusion of their abstract in the congress materials.

Oral and Poster Presentation Guidelines will be sent to the registered presenting author on **June 1, 2026**.



## ABSTRACT TOPICS

1. Basic Science
2. Translational Research
3. Medical Treatment
4. Surgical Treatment
5. Phototherapy
6. Epidemiology
7. Case Reports
8. Assessment of vitiligo severity, impact & therapeutic response
9. Artificial Intelligence in Vitiligo

## COMMON REASONS ABSTRACTS ARE REJECTED

- No learning objectives identified
- Incomplete disclosure statement
- Too little data
- Methods of study not indicated
- Insignificant study/case
- Abstract did not conform to guidelines
- Abstract is unbalanced, overly commercial
- Author or Institution mentioned in body or title
- Conclusion is questionable in relationship to data presented
- Abstract is about products or lines of business

**SUBMIT YOUR ABSTRACT HERE**

[www.VitiligoCongress.org](http://www.VitiligoCongress.org)

## SUBMISSION PROCESS

Abstracts will only be accepted via the online submission portal at [www.VitisiligoCongress.org](http://www.VitisiligoCongress.org). Abstracts sent via email, fax or mail will not be accepted. There are no restrictions on the number of abstracts you may submit.

An acknowledgment of receipt of your submission(s) will be sent automatically via email to the submitting author upon successful completion of the online submission. Abstracts will be accepted in English only.

Submitting authors and/or presenting authors may modify their submission(s) until the closing date of **April 10, 2026 at 5:00 PDT**. Modifications will not be accepted after the closing date, and late/incomplete submissions will not be accepted.

Abstracts selected for oral or poster presentation at the VIC7 program will be reproduced exactly as submitted and substitutions/edits will not be permitted. Be sure to proofread your abstract very carefully before completing your submission.

## ABSTRACT GUIDELINES

- Prepare your abstract in MS Word. Do not use presentation software (eg: PowerPoint, Keynote, Google Slides)
- **Word Limit:** Limit your abstract body to no more than 300 words including references, *not including title or learning objectives*
- **Table or Image:** You may include one (1) graphic or image per submission
- **Learning Objectives:** Include up to three (3) learning objectives. Objectives should be clear, concise statements of what the participants should be able to do after your presentation
- **Title:** should be entered in mixed case (upper and lower-case letters) as appropriate. Abbreviations may not be used in the title, unless following the full name
- **Questions to be addressed in the abstract:**
  - a) Why was the study conducted/case reported?
  - b) How was the study conducted/case reported?
  - c) What were the results of the study/case?
  - d) What is the importance of the results?
- **Disclosure Statement, Conflict-of-Interest Policy:** submitting and presenting authors must disclose any conflicts of interest and acknowledge any support from commercial interests relating to the abstract. They must disclose all relevant financial relationships with an ineligible company (any entity producing, marketing, selling/reselling, or distributing healthcare products used by or on patients) that have occurred within the past 24 months. Authors must agree with the abstract content to be considered for presentation. Identify investigational products or off-label uses of products regulated by the US/Canadian FDA at first mention, and where appropriate in the content, using generic names as opposed to brand/trade names.



## ABSTRACT BODY TO INCLUDE THE FOLLOWING

### For Studies:

1. Introduction: 2 or 3 brief sentences describing the objectives of the study.
2. Methods, Results: this should occupy  $\frac{1}{2}$  to  $\frac{2}{3}$  of the abstract, and specific data necessary to evaluate the abstract should be included. If there is concern that additional data would enhance the abstract, please strongly consider including it. Statements such as "data will be discussed at the presentation" are grounds for disqualification.
3. Conclusion: 2 or 3 sentences regarding the significance of the results in the context of the original objectives.

### For Case Reports:

1. Introduction: 2 or 3 brief sentences describing the case's relevance and importance, or what was challenging about it
2. Case Report: the discussion should be no more than 2 or 3 sentences that address why decisions were made and what is interesting/noteworthy about the case
3. Include lessons learned.

**SUBMIT YOUR ABSTRACT HERE**



## **TRAVEL SCHOLARSHIPS**


Travel scholarships will be awarded to select International and North American investigators whose abstract has been accepted for presentation at the congress. Projects that further the aims of Vitiligo Canada and the Global Vitiligo Foundation will be given priority consideration.

Global Vitiligo Foundation's mission is to improve the quality of life for individuals with vitiligo through education, research, clinical care and community support.

**Award Details:** CA \$500 (North America) – CA \$1,000 (International) to be distributed at the congress to assist with travel costs. A certificate will also be provided. Recipients are required to present their accepted abstract at VIC7.

**Who Should Apply:** Investigators who practice or conduct research in an under-represented nation/demographic, and who have submitted an abstract for peer-review consideration. Check the Travel Scholarships box when submitting your abstract if you are interested in applying.

**SUBMIT YOUR ABSTRACT HERE**



## **QUESTIONS?**

**Carrie Dick**

VIC7 Congress Secretariat,  
7<sup>th</sup> Vitiligo International Congress

Principal, Simply Eventful  
Management Inc.

e: [carrie@simplyeventful.com](mailto:carrie@simplyeventful.com)